Collaboration overview
Co-foundation a joint venture between Daewoong Pharma and Infion in 2012
Completion of “Daewong-Infion,” the first foreign plant in Indonesia, in 2013
Release of Epodion (EPO), the first biological product manufactured in Indonesia, in 2017
Benefits to Daewoong Pharma
- Established a global biologics production base
- Obtained market exclusivity through the release of Epodion, Indonesia’s first biological product
- Developed a biological product through joint-research with local experts
- Achieved full-fledged “reverse innovation” by importing the products to Korea
Benefits to partners
- Established advanced bio-infrastructure in Indonesia and seized a wide range of joint-research opportunities
- Provided with opportunities to promote/develop bio industry in Indonesia